PSNL

NASDAQ Healthcare

Personalis, Inc. - Common Stock

Diagnostics & Research

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

๐Ÿ“Š Market Data
Price$5.78
Volume1,970,617
Market Cap605.04M
Beta2.210
RSI (14-Day)42.4
200-Day MA$7.50
50-Day MA$7.06
52-Week High$11.50
52-Week Low$3.84
Forward P/E-6.12
Price / Book2.27
๐ŸŽฏ Investment Strategy Scores

PSNL scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 96/100โ€” 0
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 92/100โ–ผ -2
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 19/100โ–ฒ +3
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (96/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (4/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find PSNL in your text

Paste any article, transcript, or post โ€” the tool will extract PSNL and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.